PROTHENA CORPORATION PUBLIC LIMITED COMPANY Cash and Cash Equivalents, Period Increase (Decrease)
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) reported Cash and Cash Equivalents, Period Increase (Decrease) of $37.99 million for the 9-month period ending 2016-09-30, per its 10-Q filed 2016-11-02.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2016-11-02
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY cash and cash equivalents, period increase (decrease) for the quarter ending 2016-09-30 was -$34.37M.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY cash and cash equivalents, period increase (decrease) for the quarter ending 2016-06-30 was -$31.30M, a 125.55% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY cash and cash equivalents, period increase (decrease) for the quarter ending 2016-03-31 was $103.67M.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY cash and cash equivalents, period increase (decrease) for the quarter ending 2015-12-31 was -$17.22M.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY cash and cash equivalents, period increase (decrease) for fiscal 2015 was $77.01M, a 34.13% decline from fiscal 2014.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY cash and cash equivalents, period increase (decrease) for fiscal 2014 was $116.90M, a 125.61% increase from fiscal 2013.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY cash and cash equivalents, period increase (decrease) for fiscal 2013 was $51.82M, a 58.50% decline from fiscal 2012.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY cash and cash equivalents, period increase (decrease) for fiscal 2012 was $124.86M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2016-09-30 | -$34.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | -$65.68M derived: sum of 2 quarters · filed 2016-11-02 | $37.99M 10-Q · filed 2016-11-02 | $20.77M derived: sum of 4 quarters · filed 2016-11-02 |
| 2016-06-30 | -$31.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-02 | $72.36M 10-Q · filed 2016-08-02 | $55.15M derived: sum of 3 quarters · filed 2016-08-02 | $40.56M derived: sum of 4 quarters · filed 2016-11-02 |
| 2016-03-31 | $103.67M 10-Q · filed 2016-05-04 | $86.45M derived: sum of 2 quarters · filed 2016-05-04 | $71.86M derived: sum of 3 quarters · filed 2016-11-02 | $194.40M derived: sum of 4 quarters · filed 2016-11-02 |
| 2015-12-31 | -$17.22M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | -$31.80M derived: sum of 2 quarters · filed 2016-11-02 | $90.73M derived: sum of 3 quarters · filed 2016-11-02 | $77.01M 10-K · filed 2016-02-25 |
| 2015-09-30 | -$14.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $107.94M derived: sum of 2 quarters · filed 2016-11-02 | $94.22M 10-Q · filed 2016-11-02 | $81.65M derived: sum of 4 quarters · filed 2016-11-02 |
| 2015-06-30 | $122.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-02 | $108.81M 10-Q · filed 2016-08-02 | $96.24M derived: sum of 3 quarters · filed 2016-08-02 | $98.54M derived: sum of 4 quarters · filed 2016-08-02 |
| 2015-03-31 | -$13.72M 10-Q · filed 2016-05-04 | -$26.30M derived: sum of 2 quarters · filed 2016-05-04 | -$23.99M derived: sum of 3 quarters · filed 2016-05-04 | $84.81M derived: sum of 4 quarters · filed 2016-05-04 |
| 2014-12-31 | -$12.57M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | -$10.27M derived: sum of 2 quarters · filed 2016-02-25 | $98.53M derived: sum of 3 quarters · filed 2016-02-25 | $116.90M 10-K · filed 2016-02-25 |
| 2014-09-30 | $2.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | $111.10M derived: sum of 2 quarters · filed 2015-11-02 | $129.48M 10-Q · filed 2015-11-02 | $204.29M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-06-30 | $108.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $127.17M 10-Q · filed 2015-08-05 | $201.99M derived: sum of 3 quarters · filed 2016-02-25 | $191.34M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-03-31 | $18.38M 10-Q · filed 2015-05-06 | $93.19M derived: sum of 2 quarters · filed 2016-02-25 | $82.55M derived: sum of 3 quarters · filed 2016-02-25 | $75.49M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-31 | $74.82M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $64.17M derived: sum of 2 quarters · filed 2016-02-25 | $57.11M derived: sum of 3 quarters · filed 2016-02-25 | $51.82M 10-K · filed 2016-02-25 |
| 2013-09-30 | -$10.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | -$17.70M derived: sum of 2 quarters · filed 2014-11-04 | -$23.00M 10-Q · filed 2014-11-04 | $101.86M derived: sum of 4 quarters · filed 2015-03-13 |
| 2013-06-30 | -$7.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | -$12.35M 10-Q · filed 2014-08-05 | $112.51M derived: sum of 3 quarters · filed 2015-03-13 | |
| 2013-03-31 | -$5.30M 10-Q · filed 2014-05-05 | $119.56M derived: sum of 2 quarters · filed 2015-03-13 | ||
| 2012-12-31 | $124.86M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | $124.86M 10-K · filed 2015-03-13 | ||
| 2012-09-30 | $0.00 10-Q · filed 2013-11-12 | |||
| 2011-12-31 | $0.00 10-K · filed 2014-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |